Nrf2转录因子在炎症性肠病及其并发症中的研究进展

Research progress of Nrf2 transcription factor in inflammatory bowel disease and its complications

炎症性肠病(IBD)是一种慢性、复发性、非特异性的胃肠道炎症性疾病,包括溃疡性结肠炎和克罗恩病,其发病率呈逐年上升趋势。目前IBD的发病机制暂不明确,易导致严重的并发症,如肠纤维化和结直肠癌。IBD治疗药物包括抗生素、糖皮质激素、非甾体类抗炎药、生物制剂和免疫抑制剂等。然而,其不良反应较多,对重症患者的疗效有限。核转录因子E2相关因子2(Nrf2)在机体抗氧化和抗炎症反应中发挥着关键作用。多项研究证实Nrf2可调节IBD及其并发症的转归。本文就转录因子Nrf2在IBD中的研究进展进行综述,以期为探索IBD治疗靶点以降低其并发症提供新的启示。

Inflammatory bowel disease(IBD)is a chronic,recurrent,nonspecific inflammatory disease of the gastrointestinal tract,including ulcerative colitis and Crohn’s disease,with an increasing incidence year by year.At present,the pathogenesis of IBD is not clear,and it is prone to cause serious complications,such as intestinal fibrosis and colorectal cancer.Treatment drugs for IBD include antibiotics,glucocorticoids,non-steroidal anti-inflammatory drugs,biologics,and immunosuppressants.However,there are many adverse reactions and the efficacy of these drugs in severe patients is limited.Nuclear factor E2-related factor 2(Nrf2)plays a key role in antioxidant and anti-inflammatory responses.Multiple studies have confirmed that Nrf2 can regulate the outcome of IBD and its complications.This paper reviews the research progress of Nrf2 in IBD,so as to provide new enlightenments for exploring therapeutic targets of IBD to reduce its complications.